tm logo
Trademark Search
THERADIGM

View On IC.GC.CA

THERADIGM
REGISTERED

on 08 Dec 2021

Last Applicant/ Owned by

THERADIGM INC.

7513 Connelley DriveSuite 1Hanover, MD 21076

US

Serial Number

1896261 filed on 27th Apr 2018

Registration Number

TMA1115553 registered on 08th Dec 2021

Registration expiry Date

08th Dec 2031

Correspondent Address

Suite 2700, The Stack1133 Melville StVancouver

BRITISH COLUMBIA

CA

V6E4E5

THERADIGM

Trademark usage description

biologics, namely cells and cell lines for use in the development, testing and manufacture of therapeutics; biologics, namely cells and cell lines for Read More

Classification Information

Class [001]
Biologics, namely cells and cell lines for use in the development, testing and manufacture of therapeutics; biologics, namely cells and cell lines for use in the production of biologic substances, namely, growth factors and proteins; biologics, namely cells and cell lines for the testing of chemical substances; stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; stem cells and progenitor cells for the testing of chemical substances; bone marrow stromal cells (BMSCs) for use in the development, testing and manufacture of therapeutics; bone marrow stromal cells (BMSCs) for use in the production of biologic substances, namely, growth factors and proteins; bone marrow stromal cells (BMSCs) for the testing of chemical substances; adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; adipose tissue stromal cells (ASCs) for use in the production of biologic substances, namely, growth factors and proteins; adipose tissue stromal cells (ASCs) for the testing of chemical substances

Classification kind code

11

Class [005]
Biologics, namely cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, particularly against pathogens or cancers, or to modulate the immune system, particularly against auto-immune disease or inflammatory conditions; stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, particularly against pathogens or cancers, or to modulate the immune system, particularly against auto-immune disease or inflammatory conditions; bone marrow stromal cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, particularly against pathogens or cancers, or to modulate the immune system, particularly against auto-immune disease or inflammatory conditions; adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, particularly against pathogens or cancers, or to modulate the immune system, particularly against auto-immune disease or inflammatory conditions; cell growth media consisting of biological materials for growing cells for medical purposes; stem cells and progenitor cells for use in the production of biologic substances, namely, growth factors and proteins for medical purposes; proteins for medical use, namely, protein arrays for medical diagnosis purposes; synthetic peptides for medical purposes, namely, the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; small molecules for medical purposes, namely, clinical diagnostic reagents; telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; cell-based therapeutics for the treatment of central nervous system (CNS) disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism; Cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and MS-like diseases with the following symptoms: cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the central nervous system (CNS), namely stroke, spinal cord injury, brain injury, brain tumours, amyotrophic lateral sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, multiple sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism

Classification kind code

11

Class [040]
Treatment of materials

Comment text

CIPO Classification Code

Classification kind code

Nice

Class [042]
Pharmaceutical research and development; biological research and development; medical research and development in the field of regenerative medicine and immunotherapies; consultation and research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; consultation and research in the field of central nervous system (CNS) disorders; consultation and research in the field of stroke, spinal cord injury, brain injury, brain tumours, amyotrophic lateral sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, multiple sclerosis (MS), and MS-like diseases, namely, fibromyalgia, vitamin B12 deficiency, muscular dystrophy (MD), hypo-thyroidism, hypertension, and Arnold-Chiari deformity, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism; research and development of cell-based therapies for neurological and central nervous system (CNS) injuries and disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism; contract manufacturing of biologics, cells, and cell lines for others for medical use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system against pathogens or cancers, or to modulate the immune system against autoimmune disease or inflammatory conditions; contract manufacturing of biological materials for others for medical purposes, namely, biological cell and tissue cultures

Classification kind code

11

Class [044]
Medical treatment services in the field of regenerative medicine and immunotherapies; medical services for the treatment of central nervous system (CNS) disorders; medical services for the treatment of stroke, spinal cord injury, brain injury, brain tumours, amyotrophic lateral sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, multiple sclerosis (MS), and MS-like diseases, namely, fibromyalgia, vitamin B12 deficiency, muscular dystrophy (MD), hypo-thyroidism, hypertension, and Arnold- Chiari deformity, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism; medical treatment services, namely, using cell-based therapies for the treatment of neurological and central nervous system (CNS) injuries and disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, namely, Guillain-Barre Strohl Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIPD), Diabetic Neuropathy, Peripheral Nerve Injuries, Radiculopathies, and Small Fiber Neuropathies, and autism

Classification kind code

11

Mark Details

Serial Number

1896261

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 191
on 18th Aug 2021		Registration Fee Notice Sent
Submitted for opposition 42
on 26th May 2021		Advertised
Submitted for opposition 26
on 28th Apr 2021		Approved
Submitted for opposition 27
on 28th Apr 2021		Approval Notice Sent
Submitted for opposition 15
on 01st Feb 2021		Correspondence Created
Submitted for opposition 20
on 07th Jul 2020		Examiner's First Report
Submitted for opposition 22
on 11th Mar 2020		Search Recorded
Submitted for opposition 31
on 02th May 2018		Formalized
Submitted for opposition 1
on 30th Apr 2018		Created
Submitted for opposition 30
on 27th Apr 2018		Filed